Document is current
Any future updates will be listed below
-
Authors
Hohl, Mathias https://orcid.org/0000-0001-6946-9825
Götzinger, Felix
Jäger, Simone
Wagmann, Lea
Tokcan, Mert https://orcid.org/0009-0004-6059-1671
Tschernig, Thomas
Reichrath, Jörg
Federspiel, Jan M. https://orcid.org/0000-0002-9325-2658
Boor, Peter https://orcid.org/0000-0001-9921-4284
Meyer, Markus R. https://orcid.org/0000-0003-4377-6784
Mahfoud, Felix https://orcid.org/0000-0002-4425-549X
Böhm, Michael https://orcid.org/0000-0002-2976-2514
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 9 April 2025
First Online: 6 May 2025
Competing interests
: M.H., S.J., L.W., P.B., T.T., M.T., M.R.M. declare no competing interests. These authors declare the following competing interests: F.G. has received speaker honoraria from AstraZeneca and has been supported by the German Heart Foundation (F/61/21). J.M.F. received funding of the German Cardiology Society during parts of the study (project number: 04/2022). F.M. is supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung. Saarland University has received scientific support from Ablative Solutions, Medtronic and ReCor Medical. Until May 2024, F.M. has received speaker honoraria/consulting fees from Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor Medical, Servier, and Terumo. MB reports personal fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Servier, and Vifor. JR received funding from the Jörg Wolff foundation.
